Diffuse large B-cell lymphoma · 2 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | — | — | — | — | 1 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~5.2 mo | — | ~1 | ~R 52 PFS proxy · indirect | 3 |
2 of 2 regimens shown